TAK-573-1001
09 May 2022
Trial Summary
An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-573 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Metastatic Solid Tumors
Acronym:
TAK-573-1001
ACTRN/NCT /ethics:
NCT04157517
Scientific title:
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Metastatic Solid Tumors
Sponsor / Cooperative group:
Takeda
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I; Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2019-12-12 |
| Anticipated End Date | 2023-08-02 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Stella Papacharissiou |
| stella.papacharissiou@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Dr Rachel Roberts-Thomson |
| Recruitment Status | Recruiting |